AstraZeneca plc’s (AZN) “Hold” Rating Reiterated at Shore Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating restated by investment analysts at Shore Capital in a report released on Tuesday.
Several other research analysts have also weighed in on AZN. Credit Suisse Group reaffirmed a “neutral” rating and issued a GBX 5,000 ($66.44) target price on shares of AstraZeneca plc in a research report on Monday, June 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a GBX 5,600 ($74.41) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($68.43) price objective on AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 27th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,700 ($75.74) price objective on shares of AstraZeneca plc in a research report on Friday, June 30th. Finally, Barclays PLC raised their price objective on AstraZeneca plc from GBX 6,000 ($79.72) to GBX 6,300 ($83.71) and gave the company an “overweight” rating in a research report on Monday, July 3rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of GBX 5,172.64 ($68.73).
Shares of AstraZeneca plc (LON AZN) opened at 5188.00 on Tuesday. The stock has a 50 day moving average price of GBX 4,859.28 and a 200-day moving average price of GBX 4,907.26. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The firm’s market capitalization is GBX 65.68 billion.
WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/17/astrazeneca-plcs-azn-hold-rating-reiterated-at-shore-capital.html.
In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.